LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm announces a class action lawsuit against Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (Nasdaq: PETX). Investors who purchased or otherwise acquired Aratana shares between March 16, 2015 and February 3, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 7, 2017 lead plaintiff motion deadline.
No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
On February 6, 2017, Aratana revealed that the Center for Veterinary Medicine ("CVM") had requested more information about ENTYCE, its appetite stimulation product. Aratana told investors that it “now anticipates that ENTYCE . . . will be commercially available by late 2017” and that the CVM's demand was “in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale.”
When this information was revealed to the investing public, the value of Aratana fell, causing investors severe harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.